NCT04529044View on ClinicalTrials.gov

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 20, 2025

Study Completion Date

December 20, 2025

Conditions
Anatomic Stage IV Breast Cancer AJCC V8Metastatic Breast CarcinomaRecurrent Breast Carcinoma
Interventions
PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo PET/CT

RADIATION

Gallium Ga 68-DOTATATE

Receive 68Ga

DRUG

Lutetium Lu 177 Dotatate

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

Sponsors
All Listed Sponsors
collaborator

Advanced Accelerator Applications

INDUSTRY

collaborator

Oregon Health and Science University

OTHER

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

OHSU Knight Cancer Institute

OTHER